Auxiliis Partners With KinderPharm LLC to Provide Global Access for Paediatric Drug Development and Patients

Amsterdam, Netherlands, December 2, 2015 (Newswire.com) - Auxiliis has partnered with KinderPharm LLC, a US-based company focusing exclusively on drug development for paediatric.  KinderPharm offers a “Single-Point-of-Accountability” model for formulation development, PK/PD analysis, dose prediction in paediatric, clinical trials and regulatory submission.

By bridging the strengths of both Auxiliis and KinderPharm they complement the overall clinical trials for paediatric capabilities. This strategic partnership allows them to provide cost-effective solutions to our clients through expedited drug development processes and global sourcing of young patients.

New partnership in paediatric clinical development

Erik Hamminga, CEO

Clinical trials in Paediatric is now an integral part of drug development both in the US and EU. Although there has been significant progress in establishing the regulatory framework for the development of medicines for paediatric in the US and EU, many clinical, scientific, technical and regulatory challenges still remain for paediatric product labelling.

Auxiliis and KinderPharm are the first dedicated and fully integrated paediatric drug-development companies. Their common mission is to be the expert medicines for paediatric co-development partners and the outsourced “Paediatric Center of Excellence” for their clients.

Auxiliis and KinderPharm both have a single goal of “Bringing Better Medicines to Children”. They strive to apply the best available scientific, technical, clinical and quality practices to serve the needs of our patients and deliver value to our customers. Their integrated “one-stop” service model enables them to efficiently and cost-effectively advance products for paediatric through all the required stages of pre-clinical and clinical development.

Auxiliis and KinderPharm their comprehensive portfolio of paediatric development capabilities, combined with the talents and experience of their people, provides them with the resources needed to tackle the most challenging drug development issues.